Holen Sie sich die Stockscreener-App
0.2831
13.69%
0.0341
Handel nachbörslich:
.29
0.0069
+2.44%
Schlusskurs vom Vortag:
$0.249
Offen:
$0.249
24-Stunden-Volumen:
604.60K
Relative Volume:
0.87
Marktkapitalisierung:
$14.54M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.0502
EPS:
-5.64
Netto-Cashflow:
$-17.32M
1W Leistung:
+14.38%
1M Leistung:
-39.52%
6M Leistung:
-84.10%
1J Leistung:
-85.63%
1-Tages-Spanne:
$0.2406
$0.2999
1-Wochen-Bereich:
$0.231
$0.2999
52-Wochen-Spanne:
$0.2212
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Eterna Therapeutics Inc
Sektor
Branche
Telefon
(212) 582-1199
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Eterna Therapeutics Inc
|
0.2831 | 14.54M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eterna Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online
Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada
Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire
Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan
ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa
Eterna Therapeutics initiates $1 million stock buyback - Investing.com India
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - GlobeNewswire
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges - Investing.com Australia
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges By Investing.com - Investing.com South Africa
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India
Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times
Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK
NTN Buzztime Enters Into Material Definitive Agreement and Reports Voting Results at Annual Meeting Eterna Therapeutics Inc., a company listed on the Nasdaq Stock Market under the symbol ERNA, recently filed a Form 8-K with the Securities - Defense World
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire
Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa
Eterna Therapeutics announces share issuance and executive agreements - Investing.com India
Eterna, Factor announce license, collaboration agreement - Yahoo Finance
Eterna secures exclusive license for cell therapy tech - Investing.com India
Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire
Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World
Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks
Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com
Finanzdaten der Eterna Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):